- Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02 AstraZeneca
- AZ, Daiichi score ‘landmark’ results for ADC Datroway in triple-negative breast cancer Fierce Pharma
- AstraZeneca, Daiichi’s Datroway improves survival in triple-negative breast cancer study FirstWord Pharma
- First-Line Dato-DXd Shows OS, PFS Benefits in Immunotherapy-Ineligible TNBC OncLive
- DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast0 Business Wire
Read More: Datroway demonstrated statistically significant and clinically meaningful